title: Paclitaxel drug-eluting balloons to recurrent in-stent stenoses in autogenous dialysis fistulas: a retrospective study.
abstract: OBJECTIVE
  To assess the effect of the Medtronic paclitaxel drug-eluting balloon (DEB) on re-intervention to in-stent stenoses in autogenous dialysis arteriovenous fistulas (AVFs).
  
  
  BACKGROUND
  AVF is the optimum haemodialysis access. The commonest problem is stenosis, preventing maturation, causing inadequate dialysis or precipitating occlusion. Conventional angioplasty has a high recurrence rate. Successful drug elution in the coronary circulation led us to use DEBs in recurrent AVF stenoses since 2010.
  
  
  METHODS
  This is a retrospective study, based on prospective audit data, using DEBs on recurrent in-stent stenotic lesions in the AVF circuit of our haemodialysis population. To analyse the effect of DEBs on re-intervention, we created two Kaplan-Meier curves. The first curve compares the last "disease-free-interval" pre-DEB intervention to the first "disease-free interval" post-DEB, giving us "re-intervention-free percentage at 12 months" pre- and post-DEB. The second curve takes into account the multiple pre- and post-DEB interventions to the index lesion, and uses a marginal proportional hazards model to estimate the hazard ratio for "DEBpresent vs. DEBabsent".
  
  
  RESULTS
  From 1 September 2010 to 1 December 2013, we treated 625 AVF stenoses with endovascular techniques. In 86 of these stenoses, DEBs were used. Of the 86 DEB interventions, 37 were included for this study, 49 were excluded. In the study group, there was a significant difference in "re-intervention-free percentage at 12 months" before and after DEB: 19% vs. 69%. The hazard ratio for "DEBpresent" vs. "DEBabsent" was 0.23 (95% CI 0.14 to 0.36, p&lt;0.001).
  
  
  CONCLUSIONS
  This retrospective study suggests that DEBs significantly reduce re-intervention on recurrent in-stent AVF stenoses.
authors.affiliation: 1 Department of Surgery, Westmead Hospital, Wentworthville, Sydney, NSW - Australia.
authors.forename: Jan John
authors.initials: JJ
authors.lastname: Swinnen
authors.forename: Assad
authors.initials: A
authors.lastname: Zahid
authors.forename: David C A
authors.initials: DC
authors.lastname: Burgess
mesh_terms: D000800:Angioplasty, Balloon / Q000009:adverse effects / Q000295:instrumentation*; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D020099:Coated Materials, Biocompatible; D018572:Disease-Free Survival; D005260:Female; D006083:Graft Occlusion, Vascular / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D012008:Recurrence; D006435:Renal Dialysis; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D034941:Upper Extremity / Q000098:blood supply*; D062666:Vascular Access Devices; D014654:Vascular Patency
chemical_list: D002317:Cardiovascular Agents; D020099:Coated Materials, Biocompatible; D017239:Paclitaxel